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The analysis of exonic DNA from prostate cancers
has identified recurrently mutated genes, but the
spectrum of genome-wide alterations has not been
profiled extensively in this disease. We sequenced
the genomes of 57 prostate tumors and matched
normal tissues to characterize somatic alterations
and to study how they accumulate during oncogen-
esis and progression. By modeling the genesis of
genomic rearrangements, we identified abundant
DNA translocations and deletions that arise in a
highly interdependent manner. This phenomenon,
which we term ‘‘chromoplexy,’’ frequently accounts
for the dysregulation of prostate cancer genes and
appears to disrupt multiple cancer genes coordi-
nately. Our modeling suggests that chromoplexy
may induce considerable genomic derangement
over relatively few events in prostate cancer and
other neoplasms, supporting a model of punctuated
cancer evolution. By characterizing the clonal hierar-666 Cell 153, 666–677, April 25, 2013 ª2013 Elsevier Inc.chy of genomic lesions in prostate tumors, we
charted a path of oncogenic events along which
chromoplexy may drive prostate carcinogenesis.INTRODUCTION
Though often curable at early stages, clinically advanced pros-
tate cancer causes over 250,000 deaths worldwide annually
(Jemal et al., 2011). Identifying prostate cancers that require
aggressive treatment and gaining durable control of advanced
disease comprise two pressing public health needs. A deeper
understanding of the molecular genetic changes that occur dur-
ing the development of invasive and metastatic tumors may pro-
vide useful insights into these problems.
Genetic studies of prostate cancer have revealed numerous
recurrent DNA alterations that dysregulate genes involved in
prostatic development, chromatin modification, cell-cycle regu-
lation, and androgen signaling, among other processes (Baca
and Garraway, 2012). Chromosomal deletions accumulate early
in prostate carcinogenesis and commonly inactivate tumor sup-
pressor genes (TSGs) such as PTEN, TP53, and CDKN1B (Shen
and Abate-Shen, 2010). In addition, recent exome sequencing of
localized and castration-resistant prostate cancer has identified
base-pair mutations in genes such as SPOP, FOXA1, and
KDM6A, which implicate a range of deregulated cellular pro-
cesses in prostate tumor development (Barbieri et al., 2012;
Grasso et al., 2012; Kumar et al., 2011).
Structural genomic rearrangements also play a critical role in
prostate carcinogenesis. Roughly half of prostatic adenocarci-
nomas overexpress an oncogenic ETS transcription factor
gene (most commonly ERG) because of somatic fusion with a
constitutively active or androgen-regulated promoter (Tomlins
et al., 2007; Tomlins et al., 2005). In addition, disruptive rear-
rangements may inactivate TSGs such as PTEN or MAGI2
(Berger et al., 2011). Interestingly, analysis of prostate cancer
genomes has revealed complex ‘‘chains’’ of rearrangements,
which may result when broken DNA ends are shuffled and reli-
gated to one another in a novel configuration (Berger et al.,
2011). In theory, these DNA-shuffling events could simulta-
neously dysregulate multiple cancer genes, but the prevalence
and consequences of rearrangement chains could not be as-
sessed given the small panel of tumors sequenced.
Given the importance of structural genomic alterations in pros-
tate cancer genesis and progression, we performed whole-
genome sequencing (WGS) and DNA copy number profiling of
57 prostate cancers to define a spectrum of oncogenic events
that may operate during prostate tumor development. Through
computational modeling of rearrangements and copy number al-
terations, we inferred that the chromosomal disarray in a typical
tumor may accumulate over a handful of discrete events during
tumor development. We employ the term ‘‘chromoplexy’’ to
describe this putative phenomenon of complex genome restruc-
turing (from the Greek pleko, meaning to weave or to braid).
These complex rearrangement events occur in the majority of
prostate cancers and may commonly inactivate multiple
tumor-constraining genes in a coordinated fashion. This knowl-
edge informs a model for punctuated tumor evolution relevant
to prostate cancer and possibly other malignancies.
RESULTS
The Landscape of Genomic Rearrangement in Prostate
Cancer
We sequenced the genomes of 55 primary prostate adenocar-
cinomas and two neuroendocrine prostate cancer (NEPC) me-
tastases that developed after castration-based therapy as well
as paired normal tissue. We selected treatment-naive adeno-
carcinomas across a range of clinically relevant tumor grades
and stages (Gleason score [GS] 6 through 9; pathological stage
pT2N0 through pT4N1; Table S1 available online). Roughly
1.68 3 1013 sequenced base pairs aligned uniquely to the
hg19 human reference genome (Table S2). Sequencing of
tumor and normal DNA to mean coverage depths of 613 and
343, respectively, revealed 356,136 somatic base-pair muta-
tions with an average of 33 nonsilent exonic mutations per pri-
mary tumor (Figure 1 and Table S3A). We profiled somatic copy
number alterations (SCNAs) of DNA with high-density oligonu-
cleotide arrays (Table S3B). Additionally, we conducted tran-
scriptome sequencing on 20 tumors, along with matched
benign prostate tissue for 16 cases.To identify genomic rearrangements, we analyzed paired-end
sequencing reads that map to the reference genome in unex-
pected orientations using the dRanger algorithm (Berger et al.,
2011). We observed 5,596 high-confidence rearrangements
that were absent from normal DNA in both this cohort and an
extended panel of 172 noncancerous genome sequences (Fig-
ure 1 and Table S3C). We validated 113 rearrangements by rese-
quencing and/or PCR amplification of tumor and normal DNA
(Table S3C). We did not discover novel recurrent gene fusions
but observed several singleton events that may have led to the
overexpression of oncogenes. For example, sense-preserving
fusions joined NRF1 to BRAF (PR-4240) and CRKL to the
ERK-2 kinase gene MAPK1 (P04-1084; Figure S1A), leaving
the kinase-encoding exons ofBRAF andMAPK1 primarily intact.
Several genes, such as PTEN, RB1,GSK3B, and FOXO1, under-
went recurrent disruptive rearrangements with potential biolog-
ical consequence (Figure S1 and Table S4). Thus, rearrangement
of these genes may contribute to the development of localized
prostate cancer.
DNA Deletions and Rearrangements Reveal Signatures
of Complex Genome-Restructuring Events
Rearrangements involving cancer gene loci often occurred in
the context of a ‘‘chain’’ in which the two rearrangement break-
points map to the reference genome near breakpoints from
other rearrangements (Figure 2A, left). Such characteristic
breakpoint distributions were observed in our initial study of
seven prostate cancer genomes (Berger et al., 2011) and
appear to reflect collections of broken DNA ends that are shuf-
fled and ligated to one another in an aberrant configuration.
Given the involvement of prostate cancer genes in rearrange-
ment chains, we set out to survey chained rearrangements
systematically in order to clarify their prevalence and potential
biological consequences.
First, we determined whether additional chains could be
identified by integrative analysis of chromosomal deletions
and rearrangements. Although rearrangement chains may arise
with a minimal loss of genetic material, substantial DNA dele-
tions were often evident at the fusion junctions of chained
rearrangements (Figure 2A, right). When these deletions are
overlaid with somatic rearrangement locations on the reference
genome, the deletions create ‘‘bridges’’ that spanned the
sequence between breakpoints from two different fusions (Fig-
ure 2A, bottom right). In all informative tumors in our cohort, the
breakpoints at either end of a deletion were more often fused
to novel partners rather than to each other (thus creating ‘‘dele-
tion bridges’’ rather than ‘‘simple deletions’’; Figure S2A).
Importantly, this observation indicates that the many rear-
rangements demonstrating DNA loss near a breakpoint may
be linked by deletion bridges to additional rearrangements in
a chain.
Next, we considered whether rearrangements in a chain
might arise independently of one another, for instance, at loci
that are predisposed toward fusion because of DNA secondary
structure or nuclear proximity (Burrow et al., 2010; De and
Michor, 2011). To investigate this, we created a probabilistic
model for the independent generation of detectible rearrange-
ments across the genome (Figure S2B). Using this model, weCell 153, 666–677, April 25, 2013 ª2013 Elsevier Inc. 667
Figure 1. Somatic Alterations in 57 Prostate Tumor Genomes
WGSwas conducted on 55 prostate adenocarcinomas and two lung metastases from neuroendocrine prostate cancers (NEPC, *) along with paired normal DNA
to detect somatic rearrangements and mutations. Gains and losses of DNA copy number at sites of recurrent SNCAs were detected with Affymetrix SNP 6.0
arrays (recurrent SCNAs were not assessed for sample P07-144, hatched lines). Bottom, cancer DNA purity was evaluated by assessing allelic ratios from
sequence reads covering heterozygous single-nucleotide polymorphisms at sites of chromosomal deletion (Extended Experimental Procedures). ETS gene
fusions (ERG and ETV1) were detected by sequencing and validated by fluorescence in situ hybridization (FISH).
Also see Tables S1–S4 and Figure S1.calculated the probability that any pair of neighboring DNA
breakpoints X and Y would arise independently of each other
(PXY) on the basis of (1) their reference genome distance and
(2) the local rate of rearrangements observed in our tumor panel
(Figure 2B). As a control, we created ten simulated genomes for
each tumor, rearrangement locations being matched for chro-
mosome, local gene expression levels, sequence guanine and
cytosine content and DNA replication timing, among other fac-
tors (Extended Experimental Procedures). In addition, we
generated ‘‘scrambled’’ genomes by combining rearrange-
ments from distinct tumors, preserving locus-specific effects
that may promote double strand breakage. The observed rear-
rangements, but not the simulated or scrambled data, showed a
marked deviation from the independent model (Figure S2C) and
a statistical enhancement of chain-like patterns (Figure 2B). For
50% of rearrangements, the reference genome locations of
both breakpoints were nearer to breakpoints of additional rear-
rangements than would be expected by chance (p < 104 for
observed versus simulated or scrambled PXY values). To the
extent that our model correctly predicts the genomic distribu-
tion of independent rearrangements, these results suggest
that rearrangement chains are unlikely to arise from indepen-
dent events, thus raising the hypothesis that they occur by a co-
ordinated process.668 Cell 153, 666–677, April 25, 2013 ª2013 Elsevier Inc.Chromoplexy Generates Chained Chromosomal
Rearrangements and Deletions
Having identified chained patterns of rearrangements that may
result from interdependent alterations, we created an algorithm
called ChainFinder to search for such events systematically (Fig-
ures 3A and S3). ChainFinder employs a statistically based
search rooted in graph theory to identify genomic rearrange-
ments and associated deletions that deviate significantly from
our independent model described above and, thus, appear to
have arisen in an interdependent fashion (Extended Experi-
mental Procedures).
We used ChainFinder to survey our panel of prostate tumors
for rearrangement chains. Strikingly, this analysis revealed
numerous chains involving widely variable numbers of rear-
rangements. Some chains involved only three fusions, whereas
others contained more than 40 rearrangements that wove five
or more chromosomes together (Table S5A and Figures 3B
and S3). We have termed the putative process of genomic re-
structuring that produces these complex chains ‘‘chromoplexy.’’
Chromoplexy-related chains of five or more rearrangements (ten
or more breakpoints) were detected in 50 out of 57 tumors (88%;
Table S5B and Figure S3C), whereas 36 out of 57 tumors (63%)
contained two or more such chains. Overall, 39% of rearrange-
ments participated in chains, whereas ChainFinder detected
A B
Figure 2. Integrated Analysis of Genomic Deletions and Rearrangements Reveals Signatures of Concurrent Alterations
(A) Three scenarios by which multiple DNA double-strand breaks may be repaired are shown. Concerted repair with minimal loss of DNA (left) results in fusion
breakpoints that map to adjacent positions in the reference genome. The loss of DNA at sites of double-strand breaks may result in simple deletions (middle) or
deletion bridges (right) that span breakpoints from distinct fusions on the reference genome. Adjacent breakpoints or deletion bridges may provide evidence for
chained rearrangements.
(B) For the two breakpoints of each rearrangement (labeled A and B), the probability (P) of a second independently generated breakpoint (labeled a and b) falling
within the observed distance (L) was assessed based on the expected local rate of rearrangements (mlocal). The x and y coordinates represent the negative log ofP
for the two breakpoints in each fusion. Rearrangements near the upper right corner of the plot are unlikely to have arisen independently of other rearrangements.
Observed rearrangements are compared to simulated and scrambled data.
Also see Figure S2.chains in only 2.8% and 0.2% of rearrangements from simulated
or scrambled genomes, respectively (Figures 3C and 3D). Thus,
our statistical analysis of breakpoint distributions suggests that
chromoplexy frequently generates multiple structural alterations
in a coordinated fashion.
We noted profound phenotypic differences in chromoplexy in
subsets of prostate cancers. Chromoplexy in tumors harboring
oncogenic ETS fusions (ETS+) produced significantly more inter-
chromosomal rearrangements than ETS tumors (p < 104) and
involved a greater maximum number of chromosomes in a single
event (p = 0.009; Figures 4A–4C). Interestingly, oncogenic ERG
fusions frequently arose in the setting of chromoplexy (15 of 26
cases, 58%). Given that fusion of TMPRSS2 and ERG occurs
in the setting of androgen receptor-driven transcription (Haffner
et al., 2010), the intricate chains in ETS+ tumors could reflect
DNA injury at transcriptional hubs occupied by loci from multiple
chromosomes. Consistent with this possibility, chromoplexy in
ETS+ nuclei primarily affected regions of the genome that were
highly expressed in prostate tumors (Figure 4D) and that colocal-
ized in interphase nuclei (Figure S4A). Thus, chromoplexy in
ETS+ tumors appears to reflect a distinct process of genome re-
structuring that may be coupled to transcriptional processes.
In contrast, chromoplexy in a subset of ETS cancers resem-
bled chromothripsis (Rausch et al., 2012; Stephens et al., 2011),
a process of chromatin shattering that yields extensive DNA re-
arrangement, often of one or two focal chromosomal regions. In
particular, seven ETS tumors contained up to 7-fold more rear-
rangements than the whole-cohort average (Figure S4B). These
tumors harbored focal deletions or disruptive rearrangements
involving the chromatin-modifying enzyme gene CHD1, a puta-
tive TSG that may regulate genomic stability (Huang et al.,2012; Liu et al., 2012). The rearrangements in CHD1del tumors
were predominantly intrachromosomal both within chains (p = 2
3 104) and overall (p = 43 104; Figure S4C). Moreover, the re-
arrangements in CHD1del samples arose in late-replicating DNA
with low guanine and cytosine content (Figure S4B), generally
corresponding to gene-poor heterochromatin. An extended
cohort of 199 prostate adenocarcinomas revealed that CHD1
loss was associated with an increased number of recurrent
SCNAs (p = 1.53 108) (Figure S4C). Given the postulated roles
of CHD1 in genome stability and maintenance of chromatin ar-
chitecture (Gaspar-Maia et al., 2009), these findings raise the
possibility that CHD1 deletion may contribute to the distinctive
patterns of genomic instability observed in CHD1del tumors.
Chromoplexy Commonly Dysregulates Cancer Genes
To assess the role of chromoplexy in prostate cancer develop-
ment, we examined the genomic regions altered by deletion or
disruptive rearrangements in the context of chains. Using a list
of 17 potential prostate TSGs from the KEGG database (Kane-
hisa et al., 2012), we found that 26 of the 57 tumors (46%) had
either deletion or rearrangement of at least one gene in a chain
of three or more rearrangements (Table S5C). Inclusion of the
TMPRSS2-ERG fusion and ten putative prostate cancer genes
added nine more samples. Several cancer genes were recur-
rently deleted or rearranged by chromoplexy, including PTEN
(nine cases), NKX3-1 (eight cases), CDKN1B (three cases),
TP53 (four cases), and RB1 (two cases). Thus, chromoplexy
may conceivably influence prostate carcinogenesis by disrupt-
ing TSGs and creating oncogenic fusions.
The concurrent shuffling and deletion of multiple regions
across the genome that appears to underlie chromoplexy couldCell 153, 666–677, April 25, 2013 ª2013 Elsevier Inc. 669
Figure 3. The ChainFinder Algorithm
(A) ChainFinder creates a graphical representation of genomic breakpoints that may be linked in chains by somatic fusions, statistical adjacency, or deletion
bridges. ChainFinder assigns two neighboring breakpoints to the same chain if the p value for their independent generation (P) is rejected with a false-discovery
rate below 102. For each cycle (closed path) within the graph, all scenarios are considered where one or more rearrangements in the cycle could have arisen
independently. All rearrangements in a cycle are assigned to the same chain if every such scenario is rejected with a family-wise error rate below 102 across all
scenarios.
See the Extended Experimental Procedures for additional details.
(B) A Circos plot of chained rearrangements in a prostate adenocarcima (P09-1042). Rearrangements depicted in the same color arose within the same chain;
fusions in gray were not assigned to a chain. The inner ring depicts copy number gains and losses in blue and red, respectively.
(C) The false-positive rate of ChainFinder was assessed with simulated and scrambled genomes on the basis of observed rearrangements.
(D) For observed, simulated, and scrambled genomes, the longest chain was compared along with the portion of breakpoints in any chain. Median values, middle
quartiles, and range are indicated.
Also see Figure S3.simultaneously inactivate TSGs that are geographically distant
from each other (i.e., on separate chromosomes). We noted
several examples where multiple cancer genes were apparently
disrupted by a single instance of chromoplexy. For instance, a
chain of 27 rearrangements across six chromosomes included
the TMPRSS2-ERG fusion (21q) as well as a disruptive rear-
rangement of the prostate tumor-suppressor gene SMAD4
(18q) (Ding et al., 2011) (Figures 5A and S5). In a second
example, the adjacent CDKN1B/ETV6 tumor-suppressor genes
(12p) and the ETV3 locus (1q) were lost in the context of deletion
bridges within one chain (Figure 5B). Additional instances of
chromoplexy disrupted interacting genes in the same pathway;
for instance, codeletion of PIK3R1 (5q) with PTEN (10q) and670 Cell 153, 666–677, April 25, 2013 ª2013 Elsevier Inc.TP53 (17p) with CHEK2 (22q) occurred in two chains (Table
S5C). Thus, chromoplexy may simultaneously dysregulate multi-
ple cancer genes across the genome. Such events may provide
selective advantages to incipient cancer cells, particularly given
that the loss of some TSGs promotes prostate cancer only in
the context of specific accompanying molecular lesions (Chen
et al., 2005).
Clonal Evolution Reveals Paths of Prostate Cancer
Progression
To provide additional insight into the genomic evolution of pros-
tate tumors, we analyzed the clonal status of mutations and
deletions in our cohort. Using an approach related to previously
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Figure 4. Manifestations of Chromoplexy Vary by ETS Fusion Status
(A) Circos plots of rearrangement chains in representative tumors, grouped by the presence of ETS rearrangements andCHD1 disruption. Rearrangements in the
same chain are depicted in one color. Rearrangements in gray were not assigned to a chain. The inner ring shows copy number gain and loss in red and blue,
respectively.
(B) Rearrangement chains in ETS+ tumors contain a greater proportion of interchromosomal fusions than chains in ETS tumors. In (B) and (D), box plots indicate
median values, middle quartiles, and range.
(C) The maximum number of chromosomes involved in a single rearrangement chain (y axis), grouped by ETS status. The total number of breakpoints in chains in
each tumor is depicted on the x axis to allow comparison of tumors with similar degree of detectable chromoplexy.
(D) ETS+ chromoplexy breakpoints are enriched near DNA that is highly expressed in 16 prostate tumor transcriptomes.
Also see Figure S4.described methods (Carter et al., 2012; Nik-Zainal et al., 2012),
we exploited the extensive germline SNP genotype data
provided by WGS to assess tumor purity and the clonal statusof genomic lesions (Figures 6A and S6). Our estimates of tumor
purity based on WGS matched those produced by Absolute
analysis of SNP array data (Carter et al., 2012) (R2 = 0.99;Cell 153, 666–677, April 25, 2013 ª2013 Elsevier Inc. 671
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Figure 5. Chromoplexy May Coordinately Dysregulate Multiple Cancer Genes
(A) A chromoplexy-related chain of 27 somatic rearrangements across six chromosomes in tumor P05-3852, involving fusion of TMPRSS2 and ERG and
disruptive rearrangement of SMAD4.
(B) The putative TSGs CDKN1B, ETV6, and ETV3 were lost in the context of deletion bridges in a 25 rearrangement chain affecting three chromosomes in PR-
05-3595.
In both panels, selected rearrangements were assessed by PCR of tumor and normal DNA.
Also see Figure S5 and Table S5C.p < 104) with the exception of two samples where admixed
normal DNAwas detected only from sequencing data (Table S1).
First, we compared the clonality of deletions involving prostate
cancer genes, reasoning that lesions that arise early in tumori-
genesis or that foster rapid outgrowth would tend to be clonal,
whereas late-arising deletions would more often be subclonal.
Several common deletions were strictly clonal, including
NKX3-1 and the 3Mb region of chromosome 21q that is
frequently deleted to produce the TMPRSS2-ERG fusion (Perner
et al., 2006) (Figures 6B and S6). These events are among the
earliest detectible alterations in prostate cancer and are
frequently observed in prostatic intraepithelial neoplasia (PIN),
a prostate cancer precursor lesion (Emmert-Buck et al., 1995;
Perner et al., 2007). By contrast, deletions of PTEN were often
subclonal (p = 105 for comparison with NKX3-1 deletion clona-
lity), as were CDKN1B deletions (Figure 6C). This finding sug-
gests that PTEN and CDKN1B inactivation promotes the early
progression of prostate cancer, consistent with the association
of these events with higher-stage disease (Barbieri et al., 2012;
Halvorsen et al., 2003).
Next, we used our clonality assessments to deconvolve the
sequence of oncogenic events that gives rise to a typical prostate
tumor. Reasoning that clonal alterations must originate prior to672 Cell 153, 666–677, April 25, 2013 ª2013 Elsevier Inc.subclonal alterations within the same tumor, we examined pairs
of genes thatwere deleted in the samesample acrossmultiple tu-
mors to determine the directionality of the clonal-subclonal hier-
archy (Figure 6D). Where possible, we confirmed these relation-
ships in independent exome-sequenced tumors. A ‘‘consensus
path’’ of progression emerged, beginning with events including
the deletion of NKX3-1 or FOXP1 and fusion of TMPRSS2 and
ERG. These lesions may disrupt normal prostate epithelial differ-
entiation (Bhatia-Gaur et al., 1999; Sun et al., 2008) and affect
other oncogenic perturbations. Thereafter, lesions in CDKN1B
orTP53 accumulate; these alterationsmay lead to enhancedpro-
liferation, genomic instability and/or evasionof apoptosis. Finally,
loss of PTEN may provide a gating event in the development of
aggressiveprostate cancers. A similar assessment of pointmuta-
tion clonality (Figure 6B, lower) revealed higher overall rates of
subclonal events with the exception of early mutations as in
SPOP and FOXA1. Altogether, these results imply that prostate
carcinogenesis favors the dysregulation of cancer genes in
defined sequences, as has been suggested by studies of devel-
oping tumors in colon cancer (Fearon and Vogelstein, 1990).
Then, we investigated whether chromoplexy might continue
after cancer initiation and, thereby, contribute to the progression
of a tumor down an oncogenic path. Interestingly, several chains
Figure 6. Clonality and Evolution of Prostate Cancer
(A) A schematic representation of the clonality assessment. The allelic fractions (AFs) of sequencing reads covering heterozygous SNPs were analyzed for
the assessment of the clonality of somatic DNA alterations. A hypothetical tumor is shown, composed of normal cells, a cancer clone, and a derivative subclone.
The histograms indicate the expected SNP AFs within two deleted genes, A and B. The subclonal deletion of B yields a distinct distribution of AFs in comparison
to the clonal deletion of A.
(B) Selected deletions (top) and mutations (bottom) were classified as clonal or subclonal. Proportion test p value is listed for the indicated comparisons.
Independent samples (Barbieri et al., 2012) are included for support.
(C) An example of clonal (TMPRSS2-ERG) and subclonal (CDKN1B) deletions from the same tumor. Histograms show the proportion of sequencing reads
containing the reference allele for heterozygous SNPs in the deleted regions. A representative immunohistochemical stain for the CDKN1B protein p27 shows
discrete subclonal positivity in prostate cancer.
(D) Patterns of tumor evolution were inferred on the basis of clonality estimates. Arrows indicate the direction of clonal-subclonal hierarchy between genes that
are deleted in the same sample in multiple cases. Deleted genes are represented by circles with size and color intensity reflecting the frequency of overall
deletions and subclonal deletions, respectively. Ratios along the arrows indicate the number of samples demonstrating directionality of the hierarchy out of
samples with deletion of both genes (ratios in parentheses refer to additional samples; Barbieri et al., 2012). The inset shows a similar analysis of point mutations
(Barbieri et al., 2012).
(E) The number of recurrent SCNAs and cancer DNA purity were compared across tumors with major Gleason pattern 4 versus 3. Box plots indicate median
values, middle quartiles, and range.
Also see Figure S6.
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appeared to involve strictly subclonal deletion bridges (Fig-
ure S7A), indicating that tumors may sustain multiple rounds of
chromoplexy. Along with the observation that chromoplexy
may affect both early and late genes in the consensus path
(e.g., ERG and PTEN), these findings suggest that chromoplexy
also occurs in tumor subclones that emerge later during cancer
evolution.
Prostate Cancer Genomic Derangement Increases with
Histological Grade
Finally, we considered whether tumors with high-grade histol-
ogy (indicative of high clinical risk) might occupy positions
further along the consensus path. To this end, we quantified
recurrent SCNAs in each genome by counting amplifications
and deletions that overlapped with regions of significant SNCAs
identified by GISTICv2 analysis (e.g., the TP53 and PTEN loci)
across 199 tumors reported here and in a previous study (Bar-
bieri et al., 2012; Mermel et al., 2011). Tumors with predomi-
nantly GS 4 histology were significantly enriched for recurrent
SCNAs compared to GS 3 tumors (p = 0.0059; Figure 6E)
beyond the overall extent of SCNAs, despite similar purity of
cancer DNA and mutational burden between the two groups.
Altogether, these findings suggest that structural alterations
affecting cancer genes, many of which result from chromoplexy,
may contribute to the aggressive clinical behavior of high-grade
prostate tumors.
DISCUSSION
We have characterized somatic alterations across the genomes
of 57 prostate tumors. By systematically profiling rearrange-
ments and copy number alterations, we identified chromoplexy
as a common process by which multiple geographically-distant
genomic regions may be disrupted at once. Like other classes of
complex genomic alterations (Stephens et al., 2011; Forment
et al., 2012), chromoplexy was inferred from computational
modeling, and its mechanistic underpinnings will need to be ad-
dressed experimentally. Chromoplexy is evident in several solid
tumor types and in the majority of prostate cancers. In multiple
instances, chromoplexy altered more than one cancer gene
coordinately. In the future, systematic assessment of chromo-
plexy from WGS data could reveal groups of cancer gene alter-
ations that confer a selective advantage when sustained all at
once but activate tumor-suppressing safeguards if sustained
individually.
Although chained rearrangements could theoretically arise
over multiple cellular generations by a ‘‘sequential-dependent’’
mechanism, where the occurrence of each subsequent event
depends on the presence of a prior event (Figure S7B), such
a mechanism seems unlikely. In particular, a sequential-depen-
dent model fails to account for the many complete or ‘‘closed’’
chains we detected. For a closed chain to arise in a sequential-
dependent manner, multiple junctions from ancestral somatic
fusions would have to be rebroken precisely and fused to
each other (Figure S7B) in order to complete the chain. Even
if breakpoints in a chain could only fuse to one another,
generating the 121 observed closed chains in a sequential-
dependent process would require immensely elevated rates674 Cell 153, 666–677, April 25, 2013 ª2013 Elsevier Inc.of rearrangement in a focused region of the genome (up to
103 times the maximum observed rate; Figures S7C and
S7D). Although we cannot exclude this possibility, plausible
biological mechanism(s) could parsimoniously account for
chained rearrangements within a single cell cycle, as dis-
cussed below.
A unifying feature of chromoplexy-associated alterations is
that they occur in a nonindependent fashion; however multiple
mechanisms may account for chromoplexy. Along these lines,
our analyses have revealed distinctive patterns of chromoplexy
in ETS, CHD1del tumors. Tumors with a deletion of CHD1
demonstrated an excess of intrachromosomal chained rear-
rangements and gene deletions, DNA breakpoints being
enriched in GC-poor, late-replicating, and nonexpressed DNA.
Previous reports have proposed that similar patterns may result
from major DNA-damaging events within heterochromatic
nuclear compartments (Drier et al., 2013). These tumors showed
abundant, clustered rearrangements that often affected only one
or two chromosomes with two alternating copy number states,
perhaps indicating a chromothripsis-like process.
In contrast, chromoplexy in ETS+ tumors differed in the
aggregate from chromothripsis in several critical ways. For
example, single events joined DNA from dispersed regions of
six or more chromosomes in multiple tumors, whereas chromo-
thripsis frequently involves focal rearrangement of one or two
chromosomes (Forment et al., 2012). Overall, chromoplexy
appears more prevalent in ETS+ prostate cancer than chromo-
thripsis is in any neoplasm (Stephens et al., 2011, Forment et al.,
2012). Chromoplexy frequently involves fewer rearrangements
than the ‘‘catastrophic’’ chromothripsis defined by Stephens
et al. (2011) but may continue throughout tumor development.
Our analysis of breakpoint locations in ETS+ tumors suggests
that chromoplexy in this setting may be linked to proposed
transcriptional DNA-damaging processes (Lin et al., 2009),
potentially related to androgen receptor signaling. We stress
that this hypothesis awaits experimental validation, which could
involve fluorescence in situ hybridization (FISH) or chromosome
conformation capture before and after inducing a predicted
colocalizing event (e.g., testosterone exposure in prostate
epithelial cells). Our findings align with the observation that
ERG-overexpressing cancer cells accumulate DNA damage
and are sensitive to poly ADP-ribose polymerase inhibition
(Brenner et al., 2011). However, chromoplexy is active prior
to ETS gene fusions and generates ERG fusions in many
instances.
Whole-genome analysis also clarified the chronology of
oncogenic events in prostate cancer progression, driven, in
part, by chromoplexy. Genome-wide sequence coverage of
germline SNPs allowed us to identify DNA lesions that arose after
the founder clone was established. Subsequently, we demon-
strated a progression of events within primary tumors that ex-
pands upon array-based SCNA co-occurrence studies (Demi-
chelis et al., 2009). A consensus path of tumor evolution
begins with events such as the loss of NKX3-1 or the fusion of
TMPRSS2 and ERG. The path proceeds with the loss of
CDKN1B, TP53 and PTEN, and other progression-associated
lesions. We found that the histological grade of cancer may
partially reflect its progression down this path.
Figure 7. A Continuum Model for the
Genomic Evolution of Prostate Cancer
Oncogenic aberrations may accumulate in cancer
genomes gradually (left), by punctuated progres-
sion (middle), or in a single catastrophic event
(right). Chromoplectic rearrangements and de-
letions induce a modest to large degree of
genomic derangement over several successive
events. As indicated at the bottom, larger-scale
rearrangements that affect broader swaths of the
genome may be more difficult for a cell to survive
in andmay tend to require co-occurring oncogenic
lesions to become fixed in a tumor.
Also see Figure S7.A Continuum Model for Tumor Evolution
Tumorigenesis is classically understood to progress by a gradual
accumulation of oncogenic alterations in the genome of a pre-
cancerous cell. This textbook view was recently challenged by
the discovery of chromothripsis, in which catastrophic rear-
rangements are incurred by ‘‘shattering’’ and reassembly of focal
regions of the genome (Forment et al., 2012; Rausch et al., 2012;
Stephens et al., 2011).
We propose an expanded model for the evolution of prostate
cancer, whichmay also apply to other cancers (Figure 7). As clas-
sically understood, passenger anddriver alterationscanaccumu-
late in a cancer genome gradually over numerous cell divisions,
through point mutations, simple translocations, and focal copy
number alterations. On the opposite end of the spectrum,
extreme instances of chromothripsis can induce massive (albeit
relatively localized) DNA damage at once, often with oncogenic
consequences (Rausch et al., 2012; Stephens et al., 2011).
Between these two extremes lies a broad continuum across
which chromoplexy may often restructure cancer genomes. We
propose that oncogenic events along this continuum reflect
‘‘punctuated’’ tumor evolution, drawing an analogy from the
observation that the punctuated evolution of species may occur
rapidly between periods of relative mutational equilibrium (Gould
and Eldrige, 1977). By analogy, a tumor genome may sustain
considerable damage over several sequential and punctuated
events. Importantly, this framework accords with the observation
that chromoplexy events (1) are common, (2) may involve a wide-
ranging number of rearrangements, and (3)maycontinue after the
deletion of cancer-initiating lesions such as NKX3-1 (Figure S7).
A cancer might operate at any point along the continuum of
progression at a given time. Tumors that develop primarily atCell 153, 666–6the ‘‘catastrophic’’ end may require fewer
events and could progress more quickly,
because each event could disrupt
multiple cancer-constraining processes.
At the same time, catastrophic events
that cover diffuse genomic territory are
more liable to disrupt essential or bene-
ficial genes, thus imparting a selective
disadvantage to malignant and premalig-
nant clones that sustain such events.
Consequently, the model predicts that
survivable chromoplexy (particularlynear the catastrophic regime) is likely to involve oncogenic
alterations that compensate for the incidental inactivation of
essential genes (Figure 7). This prediction accords with the
observation that most tumors show disruption of one or more
putative prostate cancer genes within a chain. Moreover, this
model raises the possibility that the disruption of putative cancer
genes by chromoplexy may heighten the probability that such
genes represent ‘‘driver’’ events for that particular tumor. If so,
this framework may portend important implications for the use
of WGS in diagnostic and clinical studies.
In summary, this study highlights the potential for WGS data to
capture aspects of the ‘‘molecular archeology’’ of cancer devel-
opment that are missed by gene- or exome-level sequencing.
The characterization of clonal progression and chromoplexy in
emerging large panels of cancer genomes may provide insights
into tumor initiation and progression that impact cancer
detection, prevention, and therapy.
EXPERIMENTAL PROCEDURES
Sample Acquisition
Prostate tumors were obtained under protocols approved by the Broad
Institute Institutional Review Board from consented patients undergoing
radical prostatectomy or excision of soft-tissue metastases (PR-4240 and
PR-7520). Normal DNA was derived either from histologically benign prostate
tissue or peripheral blood cells. Specimens were collected at Weill Cornell
Medical College by A.T. and at various medical centers in Western Australia
in conjunction with Uropath Pty (Perth, Australia).
DNA Library Construction and WGS
Tissue cores were extracted from cancerous foci of frozen or paraffin-
embedded tumor nodules. After tissue homogenization and lysis, DNAwas ex-
tracted and assessed for quality (Berger et al., 2011). After library construction,77, April 25, 2013 ª2013 Elsevier Inc. 675
paired-end sequencing reads of 101 nucleotides were generated with an Illu-
mina GAIIx instrument. Sequencing data were aligned to the hg19 human
reference genome with BWA (Li and Durbin, 2009) and processed by the
Picard pipelines (http://picard.sourceforge.net).
Detection and Validation of Genomic Alterations
Somatic point mutations, small indels, and rearrangements were detected by
comparison of tumor and paired normal genome sequences with MuTect
(Cibulskis et al., 2013), Indelocator (http://broadinstitute.org/cancer/cga/),
and dRanger (Berger et al., 2011), respectively. dRanger was used as
described previously (Berger et al., 2011), except high-confidence rearrange-
ments required support from four or more high-quality sequencing reads and
were filtered against a panel of 176 normal tissue genomes. Somatic fusion
breakpoints were located at base-pair resolution where possible with the
BreakPointer algorithm (Drier et al., 2013). Paired-end reads from rearrange-
ments affecting cancer genes or participating in long chains were inspected
manually. A subset of rearrangements was validated by resequencing and/
or PCR amplification of tumor and normal DNA.
Chromosomal Copy Number Profiling
Segmented copy number profiles were generated from Affymetrix SNP 6.0
human SNP microarray (Affymetrix, Santa Clara, CA, USA) data as described
previously (Barbieri et al., 2012). Sites of significant recurrent copy number
alterations were identified by GISTICv2 (Mermel et al., 2011) with a log2
threshold of ±0.1 for amplification and deletion signals.
Identification of Chained Rearrangements and Deletions
The ChainFinder algorithm was implemented to detect chromoplexy from the
combined analysis of somatic fusion breakpoints and segmented copy
number profiles. ChainFinder considers breakpoints as nodes in a graph
that are connected by edges corresponding to (1) fusions, (2) deletion bridges,
or (3) breakpoint adjacency that deviates significantly from the null model of
independent breakpoints (Figure S3). Over several steps, the algorithm
evaluates potential deletion bridges and adjacently mapped breakpoints to
assign rearrangements to chains.
First, ChainFinder identifies potential deletion bridges by searching for
distinct breakpoints that plausibly correspond to the boundaries of deletion
events observed in copy number profiles. Next, a statistical analysis of all near-
est neighbor breakpoint pair distances identifies chain-like distributions of re-
arrangements. The local rate of expected independent breaks per nucleotide
(m) is calculated for 1 Mb genomic windows on the basis of (1) the rearrange-
ment frequency within the window across a panel of tumor genomes and (2)
the total number of breaks in the genome under consideration. Given m, Chain-
Finder models the probability (PXY) of observing two independently arising
fusion breakpoints within the observed distance (L) of each other on the refer-
ence genome (i.e., the p value under the null model of independent breaks):
PXY = 1 ð1 2mÞL
If PXY is rejected with a false-discovery rate of 10
2 (Benjamini and Hoch-
berg, 1995), then the corresponding breakpoints are linked in a chain.
The graph is also searched for closed paths (cycles) through nodes and con-
necting edges. For each cycle, all possible scenarios are considered by which
the contained breakpoints could have arisen independently. Breakpoints in the
cycle are assigned to the same chain if p values for every scenario can be re-
jected with a family-wise error rate (FWER) below 102.
Lastly, the graph is finalized by assigning additional sets of edges corre-
sponding to deletion bridges that could not be assigned uniquely in the first
step. The search maximizes the number of deletion bridges in cycles to find so-
lutions that account most fully for the overlap of fusion breakpoints with bound-
aries of deletion segments on the reference genome. A complete description of
ChainFinder is provided in Extended Experimental Procedures. ChainFinder
can be downloaded at http://broadinstitute.org/cancer/cga/chainfinder.
Assessment of Stromal DNA Admixture and Clonality
We used the sequence coverage from germline SNPs at sites of somatic dele-
tion to assess levels of stromal DNA admixture in sequenced samples and to676 Cell 153, 666–677, April 25, 2013 ª2013 Elsevier Inc.infer the clonal status of mutations and deletions by applying CLONET
(CLONality Estimate in Tumors; Extended Experimental Procedures). We as-
sessed the allelic fractions of SNP reads within hemizygously-deleted DNA in
order to determine the apparent proportions of DNA from normal cells at the
deleted locus. Deletions with the lowest apparent proportions of normal DNA
readswereconsidered clonal. For all other deletions,weestimated thepercent-
age of tumor cells harboring the deletion to infer the clonality of the lesion using
simulation-based error estimates. For pointmutations, the tumor allelic fraction
was corrected for stromal DNA admixture, and subclonality was inferred when
the corrected fraction differed significantly from the expected value. Lesions
present in 80% of cancer cells or less were considered subclonal.
Statistical Analyses
Quantitative comparisons of groups (e.g., numbers of rearrangements or
SCNAs) were conducted with a Mann-Whitney test unless indicated other-
wise. Box plots indicate median values and middle quartiles.
ACCESSION NUMBERS
Binary sequence alignment/map (BAM) files from WGS data as well as RNA-
seq and SNP array data were deposited in the database of Genotypes and
Phenotypes at accession number phs000447.v1.p1.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and seven tables and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2013.03.021.
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